(Q37115594)

English

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

scientific article published on 09 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study (English)

1 reference

Europe PubMed Central

18 August 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David R Gandara

4

object named as

David Gandara

1 reference

Europe PubMed Central

18 August 2017

Heinz-Josef Lenz

7

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

18 August 2017

author name string

Robert J Morgan

1

1 reference

Europe PubMed Central

18 August 2017

Lucille Leong

2

1 reference

Europe PubMed Central

18 August 2017

Warren Chow

3

1 reference

Europe PubMed Central

18 August 2017

Paul Frankel

5

1 reference

Europe PubMed Central

18 August 2017

Agustin Garcia

6

1 reference

Europe PubMed Central

18 August 2017

James H Doroshow

8

1 reference

Europe PubMed Central

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 October 2010

1 reference

Europe PubMed Central

18 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

18 August 2017

30

1 reference

Europe PubMed Central

18 August 2017

2

1 reference

Europe PubMed Central

18 August 2017

723-728

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9557-5

0 references

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Classical PKC isoforms in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Preclinical and clinical development of novel agents that target the protein kinase C family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

14 September 2017

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

29 September 2017

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

29 September 2017

Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

29 September 2017

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Successful treatment of murine melanoma with bryostatin 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3751394

27 June 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9557-5

21 January 2018

Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage therapy for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of the antiproliferative effect ofcis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20936324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9557-5

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37115594&oldid=2072526241"